On Tuesday, shares of EXACT Sciences traded down 2.51%, amounting $24.42. The molecular diagnostics company witnessed a 52-week low of $15.12 and a 52-week high of $32.85. The company's market cap is $2.17 billion.

On Monday, the company has unveiled its earning data. As per it, earnings per share (EPS) for the quarter were $0.44 and has beaten the estimate of analysts. When it came to revenue then also the company has beaten the consensus estimate. It had revenue of $8.10 million for the quarter and the estimate of $7.96 million.

It has also been found that the company has been a subject of many other recent research reports. Analysts at Mizuho have reiterated a positive rating and set the price tag of $35.00 on the company's shares.

Same goes with analysts at Benchmark Co. who also have reiterated a buy rating and set a $34.00 price target on the shares of the company. Talking about the analysts at Lake Street Capital then it has reiterated a hold rating and price tag was set at $27.00.

On Saturday, analysts at William Blair reiterated an outperform rating. Exact Sciences Corporation is focused on the early detection and prevention of colorectal cancer. It has come up with an accurate, non-invasive screening test for the early detection of colorectal pre-cancer and cancer.

Cologuard test is stool-based screening test mean to detect DNA markers, which in studies have been linked with colorectal cancer.